Insights from 2023 ASCO® Annual Meeting


 

ASCO® 2023 Insights: "Randomised Open-Label Phase II FAIM Study - Induction Standard of Care Fulvestrant & CDK4/6i With Addition of Ipatasertib in ER+/HER2- mBC Patients Without ctDNA Suppression"

87 views
August 3, 2023
Comments 0
Login to view comments. Click here to Login